Comparison of MRI/US Fusion Targeted Biopsy and Systematic Biopsy in Biopsy-Naïve Prostate Patients with Elevated Prostate-Specific Antigen: A Diagnostic Study

Huang, Chen; Huang, Yuhua; Pu, Jinxian; Xi, Qilin; Wei, Xuedong; Qiu, Feng; Wang, Ximing; Zhao, Xiaojun; Guo, Linchuan; Hou, Jianquan

doi:10.2147/cmar.s350701

Cited by 8 publications

(3 citation statements)

References 22 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The same urologist continued with SB (12-core) following the conclusion of TB. 11 All biopsy specimens were 10% formalin-fixed and subsequently sent for pathological analyses.…”

Section: Methodsmentioning

confidence: 99%

Clinical and Radiological Factors for Predicting Clinically Significant Prostate Cancer in Biopsy-Naive Patients With PI-RADS 3 Lesions

Zhang,

Hu,

Lin

et al. 2024

Technol Cancer Res Treat

View full text Add to dashboard Cite

Objective This study intends to examine the anticipatory power of clinical and radiological parameters in detecting clinically significant prostate cancer in patients demonstrating Prostate Imaging Reporting and Data System 3 lesions. Methods This was a retrospective study. The study included participation from 453 patients at the First Affiliated Hospital of Soochow University, sampled between September 2017 through August 2022. Each patient underwent a routine 12-core prostate biopsy followed by a 2 to 5 core fusion-targeted biopsy. We utilized both univariate and multivariate logistic regression analyses to identify the parameters that have a correlation with clinically significant prostate cancer. The predictive ability of these parameters was assessed using the receiver operating characteristic curve, leading to the creation of a nomogram. Results Clinically significant prostate cancer was detected in 68 out of 453 patients with Prostate Imaging Reporting and Data System 3 lesions (15.01%). Among Prostate Imaging Reporting and Data System 3a and 3b patients, 4.78% (3.09% of the total) and 33.75% (11.92% of the total), respectively, had clinically significant prostate cancer. Systematic biopsy improved prostate cancer and clinically significant prostate cancer detection rates by 7.72% and 3.09%, respectively, compared to targeted biopsy. Without systematic biopsy, there would be an undetected rate of 15% for prostate cancer and 8.13% for clinically significant prostate cancer in Prostate Imaging Reporting and Data System 3b patients. Several clinical parameters, including age, prostate-specific antigen density, lesion volume, apparent diffusion coefficient, and digital rectal examination, were statistically significant in the logistic regression analysis for clinically significant prostate cancer. The individual diagnostic accuracies of these parameters for clinically significant prostate cancer were 0.648, 0.645, 0.75, 0.763, and 0.7, respectively, but their combined accuracy improved to 0.866. A well-fit nomogram based on the identified risk factors was constructed (χ2 = 10.254, P = .248). Conclusion The combination of age, prostate-specific antigen density, lesion volume, apparent diffusion coefficient, and digital rectal examination presented a higher diagnostic value for clinically significant prostate cancer than any single parameter in patients with Prostate Imaging Reporting and Data System 3 lesions. Systematic biopsy proved crucial for biopsy-naive patients with Prostate Imaging Reporting and Data System 3 lesions and should not be omitted.

show abstract

“…The same urologist continued with SB (12-core) following the conclusion of TB. 11 All biopsy specimens were 10% formalin-fixed and subsequently sent for pathological analyses.…”

Section: Methodsmentioning

confidence: 99%

Clinical and Radiological Factors for Predicting Clinically Significant Prostate Cancer in Biopsy-Naive Patients With PI-RADS 3 Lesions

Zhang,

Hu,

Lin

et al. 2024

Technol Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…Patients who met the criteria for prostate biopsy were scheduled for transrectal prostate biopsy the day after the examination. Biopsies were performed by a number of senior urologists using the US BARD biopsy needles using the 12+X puncture method, in which 1-2 needles were punctured as the X-needle for suspicious areas suggested on nuclear magnetic resonance imaging or ultrasound, and the rest of the area was punctured by the systematic 12-needle puncture method ( 43 , 44 ). Each needle of tissue was individually placed into a fixation vial containing 10% methanol aqueous solution, marked with the hospitalization number and date of puncture, and uniformly sent to the Department of Pathology of the First Affiliated Hospital of Xinjiang Medical University for examination, where the histopathological results were recorded and diagnosed by a senior pathologist.…”

Section: Methodsmentioning

confidence: 99%

Triglyceride-glucose index is a predictor of the risk of prostate cancer: a retrospective study based on a transprostatic aspiration biopsy population

Zhou,

Li,

Muheiyati

et al. 2024

Front. Endocrinol.

View full text Add to dashboard Cite

BackgroundCurrent research suggests that prostate cancer (PCa), one of the most common cancers in men, may be linked to insulin resistance (IR).Triglyceride-glucose index (TyG index) was made for a marker of insulin resistance. We investigated the relationship between the TyG index and the risk of PCa.ObjectiveTo assess the correlation and dose-response relationship between TyG index and prostate cancer.MethodRetrospectively, 316 patients who required prostate biopsy puncture in the First Affiliated Hospital of Xinjiang Medical University from March 2017 to July 2021 were collected, and the relationship between factors such as the TyG index and prostate cancer was analyzed by Logistic regression model combined with a restricted cubic spline.Results(1) The differences in age, initial PSA and TyG index between the two groups were statistically significant; (2) Logistic regression results showed that the risk of prostate cancer in the highest quartile of the TyG index (Q4) was 3.387 times higher than that in the lowest quartile (Q1) (OR=3.387,95% CI [1.511,7.593], P=0.003); (3) The interaction results showed a significant interaction between the TyG index Q4 group and age with the risk of developing prostate cancer (P for interaction<0.001). (4) The results of the restricted cubic spline showed a linear dose-response relationship between the TyG index and the risk of prostate cancer; (5) The Receiver operating characteristic (ROC) curve results showed that the area under the curve (AUC) of the TyG index combined with initial PSA and age was 0.840, with a sensitivity and specificity of 62.5% and 93.3%, respectively.ConclusionTyG index and age are risk factors for prostate cancer, and the interaction between the TyG index and different risk factors may increase the risk of prostate cancer. TyG index has some predictive value for the risk of prostate cancer, and the risk of prostate cancer can be reduced by controlling the levels of blood lipids and blood glucose.

show abstract

“…The required sequence was obtained as described previously [10]. Transperineal 12-needle system puncture and X-needle targeted puncture was performed with the transrectal ultrasound and MRI image fusion software [11]. Imaging and pathological criteria according to PI-RADS Guidelines V2.1 and Genitourinary Society Pathology and International Society of Urological Pathology Prostate Cancer Guidelines [12].…”

Section: Mp-mri and Clinical Featuresmentioning

confidence: 99%

Extracapsular extension of transitional zone prostate cancer miss-detected by multiparametric magnetic resonance imaging

Chen

Yang

et al. 2023

J Cancer Res Clin Oncol

Self Cite

View full text Add to dashboard Cite

To demonstrate the importance of extracapsular extension (ECE) of transitional zone (TZ) prostate cancer (PCa), examine the causes of its missed detection by Mp-MRI, and develop a new predictive model by integrating multi-level clinical variables. Materials and MethodsThis retrospective study included 304 patients who underwent laparoscopic radical prostatectomy after 12 + X needle transperineal transrectal ultrasound (TRUS)-MRI-guided targeted prostate biopsy from 2018 to 2021 in our center was performed. ResultsIn this study, the incidence rates of ECE were similar in patients with MRI lesions in the peripheral zone (PZ) and TZ (P = 0.66). However, the missed detection rate was higher in patients with TZ lesions than in those with PZ lesions (P < 0.05). These missed detections result in a higher positive surgical margin rate (P < 0.05). In patients with TZ lesions, detected MP-MRI ECE may have grey areas: the longest diameters of the MRI lesions were 16.5-23.5 mm; MRI lesion volumes were 0.63-2.51 ml; MRI lesion volume ratios were 2.75-8.86%; PSA were 13.85-23.05 ng/ml. LASSO regression was used to construct a clinical prediction model for predicting the risk of ECE in TZ lesions from the perspective of MRI and clinical features, including four variables: the longest diameter of MRI lesions, TZ pseudocapsule invasion, ISUP grading of biopsy pathology, and number of positive biopsy needles. ConclusionsPatients with MRI lesions in the TZ have the same incidence of ECE as those with lesions in the PZ, but a higher missed detection rate.

show abstract

Comparison of MRI/US Fusion Targeted Biopsy and Systematic Biopsy in Biopsy-Naïve Prostate Patients with Elevated Prostate-Specific Antigen: A Diagnostic Study

Cited by 8 publications

References 22 publications

Clinical and Radiological Factors for Predicting Clinically Significant Prostate Cancer in Biopsy-Naive Patients With PI-RADS 3 Lesions

Clinical and Radiological Factors for Predicting Clinically Significant Prostate Cancer in Biopsy-Naive Patients With PI-RADS 3 Lesions

Triglyceride-glucose index is a predictor of the risk of prostate cancer: a retrospective study based on a transprostatic aspiration biopsy population

Extracapsular extension of transitional zone prostate cancer miss-detected by multiparametric magnetic resonance imaging

Contact Info

Product

Resources

About